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To maintain the integrity of an organism constantly challenged by pathogens, the immune
system is endowed with a variety of cell types. B lymphocytes were initially thought to
only play a role in the adaptive branch of immunity. However, a number of converging
observations revealed that two B-cell subsets, marginal zone (MZ) and B1 cells, exhibit
unique developmental and functional characteristics, and can contribute to innate immune
responses. In addition to their capacity to mount a local antibody response against type-2T-
cell-independent (TI-2) antigens,MZB-cells can participate toT-cell-dependent (TD) immune
responses through the capture and import of blood-borne antigens to follicular areas of the
spleen. Here, we discuss the multiple roles of MZ B-cells in humans, non-human primates,
and rodents. We also summarize studies – performed in transgenic mice expressing fully
human antibodies on their B-cells and in macaques whose infection with Simian immunod-
eﬁciency virus (SIV) represents a suitable model for HIV-1 infection in humans – showing
that infectious agents have developed strategies to subvert MZ B-cell functions. In these
two experimental models, we observed that two microbial superantigens for B-cells (pro-
tein A from Staphylococcus aureus and protein L from Peptostreptococcus magnus) as
well as inactivated AT-2 virions of HIV-1 and infectious SIV preferentially deplete innate-like
B-cells – MZ B-cells and/or B1 B-cells – with different consequences on TI and TD anti-
body responses. These data revealed that viruses and bacteria have developed strategies
to deplete innate-like B-cells during the acute phase of infection and to impair the anti-
body response. Unraveling the intimate mechanisms responsible for targeting MZ B-cells
in humans will be important for understanding disease pathogenesis and for designing
novel vaccine strategies.
Keywords: Staphylococcus aureus, Peptostreptococcus magnus, HIV-1, Simian immunodeficiency virus,
cynomolgus macaque, superantigen, protein A
To maintain the integrity of an organism constantly challenged
by pathogens, the innate immune system is endowed with a vari-
ety of cell types. Initially, B lymphocytes were thought to play
solely a role in the adaptive branch of immunity, with little
impact on innate immunity.With further investigation,however, it
became evident that B-cells can exert a number of antibody (Ab)-
independent functions, capturing, and concentrating antigen for
presentation, producing cytokines, inﬂuencing T-cell, and den-
dritic cell (DC) responses, contributing distinct functions during
the immune response in vivo, affecting lymphoid tissue struc-
tures, and, even, participating in tissue repair (Zouali, 2008). A
number of recent observations also indicate that B-cells engage
in the innate arm of immune defense (Viau and Zouali, 2005;
Abbreviations: Ab, antibody (dies); Ag, antigen; APC, antigen presenting cell;
APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor of the TNF
family; DC, dendritic cell; FO, follicular; HIV, human immunodeﬁciency virus;
iNKT, invariant natural killer T-cell; MGZ, marginal zone; MMM, metallophilic
macrophage; MZM, marginal zone macrophage; SAg, superantigen; SpA, Staphylo-
coccus aureus proteinA; SIV, Simian immunodeﬁciency virus; TD,T-cell-dependent,
TI, T-cell-independent; TLR, Toll-like receptor.
Kearney, 2008). Central to this function are marginal zone (MZ)
B-cells and B1 B-cells, two subsets of B lymphocytes that are clas-
siﬁed as “innate B lymphocytes”due to unique developmental and
functional characteristics. In rodents, these B-cell subsets exhibit
an activated phenotype that allows their rapid proliferation and
differentiation into Ab-secreting cells upon stimulation with thy-
mus independent (TI) antigens (Ags). They seem to preferentially
secrete antibodies of the IgM and IgG3 isotypes. Phenotypically,
innate-like murine B lymphocytes express the cell surface mole-
cule CD9, which distinguishes them from conventional follicular
(FO) B-cells (Won and Kearney, 2002). Whereas murine B1 lym-
phocytes locate essentially in peritoneal and pleural cavities,MZ B
lymphocytes are found principally in the MZ of the spleen, where
they represent 5% of total splenic B-cells. The MZ is recognized as
a microanatomical site that allows the transit of cells leaving the
bloodstream through the erythrocyte-rich red pulp and entering
the lymphocyte-rich white pulp. Its specialized organization facil-
itates ﬁltering of blood-borne pathogens, and initiation of innate
and adaptive immune responses. However, the MZ shows promi-
nent structural variation in different mammals – well developed
in rodents, intermediately in humans and non-human primates,
www.frontiersin.org December 2011 | Volume 2 | Article 63 | 1
3
Zouali and Richard Marginal zone B-cells
and poorly developed in the canine and feline species (Koike
et al., 1996). Whereas the white pulp is specialized in the adap-
tive response including humoral responses to thymus-dependent
(TD) Ags, the MZ is more specialized in the response to blood-
borne pathogens (bacteria, viruses) and to TIAgs (Kearney, 2008).
This functional distinction between TD and TI responses corre-
lates with the presence of FO andMZB-cells, two specialized B-cell
populations. To be fully efﬁcient in mounting Ab responses, these
B-cells must establish, in a well-controlled spatiotemporal man-
ner, interactions with specialized subsets of macrophages, DCs,
and ﬁbroblast-like cells and respond to environmental cytokines.
Here, we focus on the role of the MZ B cell subset in immune
defense and discuss how infectious agents can deploy strategies to
subvert this important arm of immunity in mice, and in human
and non-human-primates.
THE MARGINAL ZONE OF THE SPLEEN, FROM STRUCTURE
TO FUNCTION
Several observations indicate that the human spleen plays an
important role in defense against infectious agents. For exam-
ple, the low Ab response found in young and aging individuals
is associated with immaturity and compromised functions of the
spleen MZ, respectively (Timens et al., 1989). Second, individuals
with splenic dysfunctions or splenectomy are highly susceptible to
infection with Streptococcus pneumoniae, Haemophilus inﬂuenzae,
Neisseriameningitidis, or other encapsulated bacteria, and this sus-
ceptibility correlates with a deﬁcit in circulating MZ B-cells and a
lack of Ab responses against these pathogens. Third, patients with
common variable immunodeﬁciency presenting with recurrent
infection of the respiratory tract and chronic lung disease have
an extremely low frequency of IgM memory B-cells and do not
produce anti-polysaccharide IgM (Carsetti et al., 2004). Fourth,
splenic dysfunctions may also occur in patients with sickle-cell
anemia known to manifest increased susceptibility to infection
(Wong et al., 1992) or inﬂammatory bowel disease (Di Sabatino
et al., 2007), in whom both impaired IgM production by MZ B-
cells and reduced phagocytosis of opsonized particles prevent the
clearance of encapsulated bacteria. Taken together, these observa-
tions indicate that the spleen exerts speciﬁc protective functions
that cannot be totally replaced by other lymphoid organs during
adult life. Yet, a normal blood MZ B-cell compartment is present
in young children with congenital asplenia, suggesting that MZ
B cell precursors can colonize alternative sites to develop (Weller
et al., 2004). Similarly, cells with morphology and phenotype of
MZ B-cells have been observed in the subcapsular sinus of lymph
nodes, under the dome epithelium of Peyer’s patches in the gut
and in the crypt epithelium of tonsils (Spencer et al., 1998; Dono
et al., 2000). It remains to be established whether these cells play a
role in the defense against encapsulated bacteria.
MARGINAL ZONE B-CELLS
In the mouse, MZ B-cells differ in many respects from the pre-
dominating subset of mature re-circulating FO B-cells. Whereas
the latter are small surface (s)IgMlowsIgDhigh B-cells, the former
are intermediate-sized sIgMhighsIgDlow cells located in a distinct
area surrounding the B cell follicles and the periarteriolar lym-
phoid sheath. MZ B-cells exhibit a low re-circulating potential
and are involved in type-2 TI responses to lipopolysaccharide
Ags that form the major constituent of cell walls of encapsulated
bacteria, such as S. pneumoniae,N.meningitidis, andH. inﬂuenzae.
Ex vivo, puriﬁed MZ B-cells respond generally more vigorously to
mitogens like LPS, dextran-conjugated anti-IgM or IgD Abs, or
CD40 ligation, than FO B-cells. Phenotypically, they exhibit a pre-
activated state (pyroninophilic cytoplasm, less condensed nuclear
chromatin, complement receptor CD21high, CD23low, CD35high,
and higher basal levels of CD80 and CD86). Reduced levels of
CD23, a negative regulator of B-cells, on MZ B-cells may allow
them to produce a rapid Ab response in comparison to FO B-cells.
These remarkable features, together with their unique anatomi-
cal location in the spleen account for the fact that MZ B-cells are
endowed with powerful immunological functions.
In rodents, splenic MZ B-cells are a heterogeneous population
of cells comprising ≈80% of naive B-cells and a minor fraction
(20%) with signs of Ag-selection (Dammers et al., 2000). Naïve
MZ B-cells harbor germline-encoded variable region genes and
produce polyreactive Abs that play a crucial role in the ﬁrst-line of
defense against blood-borne infectionswith encapsulatedbacteria.
Such polyreactive naturally occurring Abs are essential in the pri-
mary immune response against pathogens (Zouali, 2009). Thus,
by providing a strategically located buffer of polyreactive B-cell
receptors (BCRs) in the spleen, naive MZ B-cells form an integral
part of innate immunity.
THE FUNCTIONS OF MZ B-CELLS
In addition to the involvement of MZ B-cells in the initial response
to TI Ag, other studies demonstrate that activated MZ B-cells are
potent protein Ag presenters to CD4+ T-cells, and have the abil-
ity to induce Ag-speciﬁc T-cell clonal expansion both in vitro and
in vivo (Attanavanich and Kearney, 2004). Speciﬁcally, MZ B-cells
canmount rapid and efﬁcient primary responses to soluble protein
Ag and have an extraordinary ability to promote T-cell prolifera-
tion and cytokine production after immunization with proteinAg.
Within a few hours of in vivo Ag priming, MZ B-cells are far supe-
rior to FO B-cells in the activation of naive CD4+ T-cells in vitro,
and higher levels of B7.2 are expressed on the cell surface of MZ
compared with FO B-cells after Ag stimulation.
As discussed above,MZ B-cells comprise an innate subset local-
ized to the marginal sinuses of the spleen. Because they have
the capacity to respond to speciﬁc foreign Ag more rapidly than
FO B-cells, they provide early immune responses to blood-borne
particulate Ags. In addition to being an early source of pathogen-
speciﬁc T-cell-independent IgM, MZ B-cells serve to bridge the
innate and adaptive immune systems. For example, studies of
the spirochete Borrelia hermsii showed that MZ B-cells directly
associate with blood-borne Borrelia spirochetes and are activated
in vivo to produce pathogen-speciﬁc IgM within 72 h of infection
(Belperron et al., 2005).Whenmicewere depleted fromMZB-cells
to determine their contribution to host defense against B. burgdor-
feri, the deﬁcient animals showed a reduced B. burgdorferi-speciﬁc
IgM, elevated pathogen burden, and reduced levels of B. burgdor-
feri-speciﬁc IgG that correlated with diminished splenic CD4+
T-cell responses (Belperron et al., 2007). These results demonstrate
a role for MZ B-cells not only in Borrelia-speciﬁc IgM production,
but also in promoting the early adaptive T- and B-cell responses
Frontiers in Immunology | Molecular Innate Immunity December 2011 | Volume 2 | Article 63 | 2
Zouali and Richard Marginal zone B-cells
to this spirochete. They reveal an important role for this B-cell
subset in priming splenic T-cells and the subsequent development
of T-cell-dependent IgG responses during infection.
Recent studies suggest that in addition to TLR signaling in
DCs, direct TLR-mediated activation of B-cells is also required
for eliciting humoral immune responses. Thus, murine B-cells
can be stimulated in vitro by TLR4 and TLR9 ligands to prolifer-
ate and secrete Ab (Whitlock and Watson, 1979). In vivo, chimeric
mice in which only B-cells are deﬁcient in TLR signaling fail to
mount Ab responses to protein Ags given with adjuvants (Pasare
and Medzhitov, 2005). Consistent with these observations, ago-
nists to intracellular and extracellular TLRs activate MZ B-cells
in vivo and promote their release from the MZ, thus potentially
accelerating the kinetics of the Ag-speciﬁc IgM response (Rubtsov
et al., 2008). In response to TLR agonists, MZ B-cells proliferate
and exhibit a phenotypic maturation process characterized by an
increased expression of MHC class II, CD40, and CD86 molecules.
According to the TLR agonist used, they also display a different
cytokine proﬁle (Bialecki et al., 2009). The fact that MZ B-cells
are well equipped in TLRs and that their stimulation leads to cell
proliferation, maturation (i.e., cytokine production) and Ab pro-
duction (Rubtsov et al., 2008) further supports the conclusion that
they play a role as innate sensors in MZ B cell-mediated immune
responses.
Strikingly, MZ B-cells are able to promote optimal immune
responses by interacting with other cell types. For instance, they
can transport immune complexes to follicular DCs and deposit
them on their surface, or process Ag for direct presentation on
MHC class II molecules to naïve CD4+ T-cells (Martin and Kear-
ney, 2002; Attanavanich and Kearney, 2004). Further evidence
comes from studies of invariant NKT (iNKT) cells, a subset of
NKT cells that recognize exogenous and self glyco/lipid Ags pre-
sented by the non-classical class I molecule CD1d expressed on
Ag presenting cells (APC; Bendelac et al., 2007). Upon primary
stimulation, iNKT cells produce large amounts of immunoregula-
tory cytokines, including IFN-γ and IL-4 that lead to downstream
activation of DC, NK cells, B-cells, and conventional T-cells (Ben-
delac et al., 2007). In the mouse, iNKT cells localize in the splenic
B-cell area, including the MZ. In the presence of accessory cells
(DC), MZ B-cells stimulate the release of both IFN-γ and IL-4 by
iNKT cells, strongly suggesting that MZ B-cells have the potential
to condition iNKT cell functions in vivo (Bialecki et al., 2009). The
observation that MZ B-cells play a role in iNKT cell activation
in vivo, together with the fact that the BCR facilitates the uptake of
particulate Ags and their transport to CD1d-containing endocytic
compartments, reinforce the view that the MZ B cell/iNKT cell
interactions play important roles in the immune response.
It is remarkable that theMZ is a dynamic structure inwhich cell
retention and trafﬁcking require speciﬁc cell interactions. Histo-
logically, the murine MZ comprises mucosal addressin cell adhe-
sion molecule 1 (MAdCAM-1+) sinus-lining reticular endothe-
lial cells, marginal metallophilic macrophages (MMM) that stain
with Abs to the Monocyte/Macrophage Marker (MOMA-1), and
SIGN-R1+ (speciﬁc intracellular adhesion molecule-grabbing
non-integrin receptor 1) MZ macrophages (MZM). Apart from
MZ B-cells, MZM represent the other predominant cell type of
the MZ. They are distinct from MMM which express the marker
MOMA-1 and are located at the border of the marginal and
follicular zones. MZM are interspersed in several layers within
the MZ, and express the markers MARCO, a scavenger receptor
belonging structurally to the class A receptor family, and ER-TR9
which is identical to the C-type lectin SIGN-R1. Mouse MZM are
highly phagocytic and responsible for clearance of blood-borne
TI antigens and apoptotic material entering the spleen. Whereas
MARCO binds a range of microbial Ags, including Staphylococcus
aureus and Escherichia coli, SIGN-R1 is the predominant recep-
tor for uptake of S. pneumoniae and polysaccharide dextran by
MZMs (Lanoue et al., 2004; Birjandi et al., 2011). Importantly,
the dialog between MZ B-cells and MZM is essential to main-
tain the MZ structure and to allow efﬁcient immune responses
(Karlsson et al., 2003). For example, once MZM bind pathogen,
they establish direct cell–cell interactions with MZ B-cells that
are required for potent responses (Chen et al., 2005), allowing
the clearance of Leishmania donovani and Listeria monocytogenes
(Odermatt et al., 1991; Aichele et al., 2003). In another model
system, MZ B-cells were found to regulate the expression of mol-
ecules on macrophages that are important for trapping Ag, which,
in turn, is required for Ag capture by the B-cells, thus modulat-
ing MZM functions that are important to protect against lethal
infection (You et al., 2011). Consistently, the decreased frequency
of MZM and MZ B-cells seen in old mice correlates with disrup-
tion in the marginal sinus and reduced capacity to bind and clear
pathogen-like particles (Birjandi et al., 2011). Thus, MZ B-cells
not only provide a link between the innate and adaptive immune
responses, but they also function as regulatory cells that control
the phenotype and function of other cells involved in the acute
innate immune response.
HUMAN MZ B-CELLS
Studies of the Ig genes expressed by MZ B-cells of normal
untreated, non-intentionally immunized rodents revealed that
the majority of the splenic cells exhibit little mutations in their
rearranged VH genes and, thus, represent naive B-cells, and that a
minor fraction (20%) of the MZ B-cell pool express somatically
mutated VH genes (Dammers et al., 2000). These features con-
trast with the situation in the human spleen where the majority
(>85%) of splenic MZ B-cells are somatically mutated (Dunn-
Walters et al., 1995; Tierens et al., 1999), suggesting that memory
B-cells constitute the majority of spleen MZ B-cells. These diversi-
ﬁcation characteristics could either reﬂect a heavy load of somatic
hypermutation occurring during clonal expansion in the MZ, or
a process of somatic hypermutations acquired in germinal centers
(GCs) at distant sites before cellmigration to theMZ.However, the
microanatomical structure of the human spleen differs from that
of rats and mice with respect to MZ organization and the presence
of a so-called perifollicular zone surrounding the MZ (Steiniger
et al., 2006). In contrast to rodents, the human spleen lacks a mar-
ginal sinus, and the MZ surrounds B-cell follicles, but not the
PALS (periarteriolar lymphatic sheath) in the T-cell rich area. Yet,
an additional compartment, the perifollicular zone, which sur-
rounds B-cell follicles, makes a transition between the MZ and the
red pulp (Figure 1). This zone has a dynamic composition with
strong similarities with the red pulp in terms of terminal sinuses,
blood-ﬁlled spaces, sheathed capillarieswithout endothelial lining,
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FIGURE 1 | Organization of the follicular and MZ B-cell compartments
in human. Sections of human spleens were stained with mAbs to CD20 or
alpha smooth muscle actin (ASM). (A)The network of ﬁbroblast-like cells
stained by the anti-ASM mAb subdivides the outer and inner MZ around the
follicles, and separates theT-cell zone from the red pulp. Original
magniﬁcation ×10. (B) A ring of B-cells can be seen outside the ASM+
network in both theT and B-cell zones. Original magniﬁcation ×10. (C,D)
Secondary B-cell follicles with a central germinal center, the mantle zone
(intense blue in C, black arrow), the MZ, and the perifollicular zone (white
arrow) with less dense accumulation of B-cells. Original magniﬁcation ×20.
(E) Schematic representation of theT- and B-cell zones in human spleen.
GC, germinal center; PALS, periarteriolar lymphatic sheath; MZ, marginal
zone.
and scattered B- andT-cells. Because terminal vessels directly open
into the perifollicular zone,Ags and lymphocytes likely exit the cir-
culation in this structure and trafﬁc either to the MZ or to the red
pulp (Timens, 1991). A meshwork of ﬁbroblast-like cells, express-
ing alpha smooth muscle actin (ASM) and MadCAM-1 subdivides
the MZ into large inner and small outer compartments, the lat-
ter being in close contact with the perifollicular zone. Along the
network of ASM-positive cells, a small ring of B-cells delimits the
T-cell zone from the red pulp,whereas a ring of T-cells is frequently
present between the inner and outer MZ (Steiniger et al., 2006).
Interestingly, the MZM and MMM subsets found in rodents are
lacking in humans.However,macrophages expressingCD68 (lyso-
some/macrosialin) and CD169 (sialoadhesin) preferentially form
sheaths around capillaries in the perifollicular area, but can be also
present as scattered cells expressing DC-SIGN (CD209; Steiniger
et al., 2006). It remains unclear whether these macrophages can
replace MZM in trapping pathogens and interacting with MZ
B-cells. In humans, CD11c+CD205+ DCs are intertwined with
MadCAM-1+ cells at the inner border of the perifollicular zone
whereas plasmacytoid DCs are absent from MZ at the steady state
(Steiniger et al., 2006; Pack et al., 2008).
Mouse and human MZ B-cells can be distinguished from FO B-
cells as being SIgMhighCD21highSIgDlow CD23−. In humans, MZ
B-cells are CD27+ memory B-cells and generally express somati-
cally diversiﬁedVH genes (Dunn-Walters et al., 1995; Tangye et al.,
1998; Weller et al., 2004). Intriguingly, CDR3 spectratyping evi-
denced a higher clonal diversity inMZB-cells than in other human
memory B-cells (Weller et al., 2008). Starting from less than 1%
in the cord blood, the frequency of MZ B-cells increases concomi-
tantly with that of switched memory blood and spleen B-cells, and
the frequency of Ig variable region gene mutation in blood MZ B-
cells reaches adult value by 2–4 years of age. Overall, the available
ﬁndings suggest thatMZB-cells constitute a pool of pre-diversiﬁed
B-cells, with a slow rate of renewal, which can be rapidly mobi-
lized by pathogens or polysaccharidic vaccines. BecauseMZB-cells
persist in CD40 or CD40L-deﬁcient patients, it has been suggested
that they develop independently of GCs and T-cells (Weill et al.,
2009). The fact that BAFF and APRIL have been shown to support
TI responses, activation-induced cytidine deaminase expression
and hypermutation, and that BAFF is produced in the MZ may
indicate that these cytokines contribute to diversiﬁcation of MZ
B-cells (Litinskiy et al., 2002).
SUBVERSION OF INNATE-LIKE B CELL IMMUNITY BY
SUPERANTIGENS
Studies of the confrontation of the mammalian host with infec-
tious agents led to identiﬁcation of subversion mechanisms that
allow pathogens to persist in the organism (Hasler and Zouali,
2003). Such a strategy is used by S. aureus to impact MZ B-cells.
This bacterium is a leading cause of human infections world-
wide. It causes a variety of diseases, including impetigo, cellulitis,
food poisoning, toxic shock syndrome, necrotizing pneumonia,
endocarditis, and sepsis (Archer, 1998). Our understanding of the
molecular mechanisms used by this pathogen to avoid destruction
by host defenses remains limited. Even tough S. aureus produces
a variety of virulence factors, protein A (SpA) is the prototype
staphylococcal surface protein. In addition to its Fc IgG binding
capacity, which can be used for Ig puriﬁcation, SpA also interacts
with the VH region of Igs, a property responsible for its super-
antigen (SAg) activity for B-cells (Zouali, 1995, 2007b). To test the
effect of SpA in vivo, we used “XMG2L3” transgenic mice whose
mouse Ig loci were inactivated and their humoral immune sys-
tem restored by introduction of human VH, Vκ, and Vλ loci in a
germline conﬁguration. As a result, their B lymphocytes express
fully human surface Igs, and secrete IgM and IgG2 bearing κ or
λ-human L-chains. A remarkable feature of these mice is that half
of the VH genes present on the translocus belong to the VH3 gene
family, a ﬁgure that closely mimics the complexity of the human
Ig VH locus. When immunized, they mount antigen-speciﬁc anti-
body responses with somatic mutation, isotype switching and
afﬁnity maturation.
Analyzing SpA effects in peripheral lymphoid organs, we
found that a single injection of SpA to the transgenic human-
ized mice reduces B-1a cells in the peritoneal cavity and VH3+
B-cells in the spleen. Importantly, even repeated administrations
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of this SAg do not modify B-1b or B-2 cell numbers (Viau
and Zouali, 2005). In the spleen of treated mice, we stud-
ied in detail the fate of various B cell subpopulations, includ-
ing newly formed B-cells (B220+CD23−CD21−), transitional
T1 (B220+CD21+IgM+), transitional T2 (B220+CD21−IgM+),
re-circulating FO (B220+CD23+CD21+) and resident MZ B-
cells (B220+CD23−/lowCD21+). Remarkably, we found that SpA
induced a speciﬁc reduction of the MZ subpopulation (Viau and
Zouali, 2005). The molecular basis of this speciﬁc deletion of MZ
B-cells, as opposed to FO cells, remains unresolved. It is likely that
the disparity in responses of MZ and FO B-cells to SpA reﬂects a
functional dichotomy in these two splenic subpopulations.
In single cell PCR-based studies and sequencing of the
expressed genes,we demonstrated that the reduction of MZB-cells
in SpA-treated mice reﬂects the decrease of the absolute num-
ber of VH3-expressing B-cells in this subset (Viau and Zouali,
2005). Thus, the effect is a direct consequence of VH3+ B-cell
targeting capacity of SpA. To determine whether the SpA B-cell
deleting potential had functional consequences, we immunized
SpA-treated mice with either a type-2 TI Ag (DNP-Ficoll) or a TD
Ag (tetanus toxoid). These studies disclosed a speciﬁc impact of
SpA on the type-2 TI response (Viau and Zouali, 2005).
It is remarkable that, investigating the in vivo effects of another
bacterial SAg, protein L from Peptostreptococcus magnus, we found
a similar impact on B-cells with innate-like functions. In contrast
to protein A, protein L from P. magnus binds predominantly to
κ-light chains, regardless of the H-chain subclass, and it has afﬁn-
ity for all Ig classes. Since approximately two-thirds of human Igs
have κ-type L-chains, protein L interacts with a signiﬁcant pro-
portion of Igs. In vitro, protein L acts as a SAg for human Igs. It
also cross-links the VL domains of IgE bound to Fcε receptors,
and stimulates the release of histamine by basophils and mast cells
(Zouali, 1995, 2007a). To study protein L effects in vivo, we used
“5-feature” transgenic mice whose endogenous loci coding for the
H- and L-chains have been inactivated, and human H-, κ, and
λ chain transloci were “knocked-in.” Humanized mice injected
intraperitoneally with 1mg of recombinant protein L led to a loss
of mature B-cells in the peripheral immune system and a reduc-
tion of protein L+ B-cells in the spleen. Further characterization
of B-cell subsets in protein L-injected mice revealed a depression
of MZ B-cells in the spleen and a reduction of CD5+ B-cells (B1)
in the peritoneal cavity (Viau et al., 2004b).
IMPACT OF HIV-1 ON INNATE-LIKE B-CELLS IN A MODEL OF
MICE EXPRESSING FULLY HUMAN IGS
Although there is no convincing evidence that HIV-1 infects B-
cells, marked changes in B-cell responses have been described,
including hyper-gammaglobulinemia, increased expression of
markers of activation and terminal differentiation, augmented
secretion of Igs in vitro and in vivo, and increased susceptibility
to apoptosis (Viau and Zouali, 2001; Cagigi et al., 2008). Sev-
eral longitudinal and cross-sectional studies have indicated that
most of these B-cell abnormalities are directly associated with
high levels of HIV-1 plasma viremia, and its reduction, by effective
anti-retroviral therapy, diminishes polyclonal and HIV-1-speciﬁc
Ig levels, partially restores APC function and responsiveness to
T-cell help. Even efﬁcient anti-retroviral therapy only partially
normalizes expression of B-cell activation markers, proportions
of memory B-cells, and terminal differentiation (Viau and Zouali,
2001;Cagigi et al., 2008). Thus,B-cell dysfunctions represent a cen-
tral feature of chronic HIV-1 infection, with potential pathogenic
consequences.
Although the mechanisms of these abnormalities remain the
focus of much investigation, direct and indirect effects of HIV-
1 remain possible. One possibility is that the capacity of gp120
to act as SAg for human B-cells could account directly for the
biased repertoire expression. In vitro, gp120 binds human VH3+
Igs, and activates proliferation and differentiation of VH3+ B-cells
(Berberian et al., 1993). As it is hard to assess the consequences of
these in vitro and ex vivo observations in patients, we used mice
into whose genome human Ig loci have been introduced, along
with functional inactivation of the endogenous mouse IgH and
Igκ loci (Viau et al., 2007). In these transgenic animals, B-cells
expressing a virtually full human Ig repertoire develop, allowing
investigation of the in vivo consequences of confronting B-cells
expressing human Igs with soluble gp120 or inactivated viri-
ons. We found that soluble gp120 induced an inversion in the
B-1a/B-1b cell ratios, without impacting B-2 cells or affecting
substantially the T-cell compartment. Treatment with inactivated
AT-2 virions speciﬁcally and dramatically depressed B-1a cells,
which represent the majority of B1 cells in normal mice. The
observed B-cell changes were associated with a functional alter-
ation of the humoral response to tetanus toxoid. Thus, the results
reveal a capacity of HIV-1 to speciﬁcally impact a highly special-
ized B cell subpopulation. Because there is evidence that human
IgM memory B-cells are functionally equivalent to murine B-1a
cells, our ﬁndings suggest that gp120 may have a direct deleting
activity on B-cell memory.
IMPACT OF SIMIAN IMMUNODEFICIENCY VIRUS ON MZ
B-CELLS IN THE CYNOMOLGUS MACAQUE
In addition to the presence of immature/transitional CD10+ or
exhausted CD27 negative B-cells in the peripheral blood (Ho
et al., 2006), alterations in the architecture of GC and splenic
MZ were observed in HIV-infected patients with advanced disease
(Legendre et al., 1998; Wilkins et al., 2003). Despite the presence
of polyclonal activation, HIV-1-speciﬁc Ab responses are strongly
impaired, resulting in a decreased response to natural or vaccine TI
andTDantigens (Scamurra et al., 2000;Hart et al., 2007), and a loss
of peripheral memory B-cells (De Milito et al., 2001; Chong et al.,
2004; Titanji et al., 2006). The view that spleen dysfunctions occur
during HIV infection is also supported by observations showing
that an increased frequency and severity of infection by encap-
sulated bacteria is a sign of AIDS progression in HIV-1-infected
children that has been correlated with histological immaturity or
dysfunction of the spleen MZ in HIV-negative children (Timens
et al., 1989),
Because recent studies in humans suggest that virus-induced
early activation has a major role in shaping the repertoire of mem-
ory B-cells and plasma cells, and in trafﬁcking (Badr et al., 2005;
Titanji et al., 2005; He et al., 2006; Hart et al., 2007), it became
important to examine changes in B-cell subsets in different lym-
phoid organs during the acute phase of infection. As the study of
primary HIV infection in humans is limited by the availability of
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FIGURE 2 | Loss of MZ B-cells and switched memory B-cells during the
acute phase of SIV infection. Macaques were infected intravenously with
the pathogenic SIVmac251 strain. For each macaque, blood samples were
taken before infection and every 3 days post-infection (dpi). Three groups of
ﬁve macaques were sacriﬁced 14, 21, and 28 dpi. At euthanasia, spleen,
peripheral blood, and mesenteric lymph nodes (LN) were collected from
SIV-Infected animals and from four non-infected control animals. (A) Plasma
viral load was determined by real-time PCR as described (Peruchon et al.,
2009). Horizontal bars indicate median values. (B) Absolute numbers of
blood CD4T-cells were determined in each animal as described (Peruchon
et al., 2009) before infection and 11–12 dpi when they reached their lowest
values (nadir). Horizontal bars indicate median values. (C) CD27 and SIgD
expression was studied by three-parameter immunoﬂuorescence analysis
on CD20-gated populations from various organs. Cells were gated on
forward and side scatter (R1), and then on CD20 (R2) expression. CD27 and
SIgD expression on CD20+ cells is shown on a representative dot plot of
peripheral blood mononuclear cells staining. The percentage of positive cells
is indicated in each quadrant. Flow cytometry plots depict log10
ﬂuorescence. (D–F) Shown are the mean percentages of naïve
(SIgD+CD27−, open area), switched memory (SIgD−CD27+, hatched area),
and MZ (SIgD+CD27+, black area) B-cells for each group of animals (n =3).
(D) Shows data in peripheral blood before and after exposure to SIV. (E)
Shows data from the spleen of non-infected animals (ctl, n =4) and
SIV-infected animals (n =3 for all groups). (F) shows data from LN of
non-infected animals (ctl, n =4) and SIV-infected animals (n =5 for all
groups). (G) Spleen sections from non-infected macaques (Ctl) and from
SIV-infected animals collected 14, 21, and 28 dpi were stained with alpha
smooth muscle actin (ASM) mAb for visualization of the MZ. Shown are
staining for one representative animal from each group. White bars indicate
the MZ region width as measured in 19–22 ASM-stained regions in each
spleen. Mean values±SEM are 132±14μm for Ctl, and 114±23, 136±27,
106±17μm for macaques infected for 14, 21, and 28 dpi, respectively.
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lymphoid organs and by the difﬁculties associated with perform-
ing longitudinal investigations using tissues other than peripheral
blood, we used a model of experimental pathogenic infection in
cynomolgus macaques by Simian immunodeﬁciency virus (SIV),
a suitable model that reproduces the long-lasting HIV-1 disease
(Peruchon et al., 2009). We found a decrease in switched memory
andMZB-cells that differed in intensity and kinetics in the various
organs (Figure 2). This decrease correlates with rapid homing of
peripheral B-cells into secondary lymphoid organs and their pref-
erential retention in the spleen and the small intestine where SIV
replication is particularly intense. Although the histological size
of the MZ did not signiﬁcantly vary, the frequency of MZ B-cells
decreased steadily in the spleen and transiently before 21 dpi in
peripheral and mesenteric lymph nodes. The MZ B-cell loss was
concomitant with a transient peak of apoptosis on 14 dpi and their
increased commitment to TI terminal differentiation (Figure 3).
FIGURE 3 | B-cell apoptosis and antibody production in acutely
SIV-infected macaques. (A) Spleen B-cells were puriﬁed from macaques
using PE-conjugated anti-CD20 mAb and PE-conjugated magnetic beads.
They were cultured for 24 h with medium or with 25μg/ml rabbit anti
Ig(H+L) Ab before staining with DAPI. Apoptotic cell percentages were
determined in splenocyte cultures from four non-infected animals (Ctl,
diamond symbols) and from two SIV-infected macaques sacriﬁced on 14,
21, or 28 dpi (circle symbols). Each point represents the percentage of
hypodiploid B-cells from one animal. Bars represent the mean percentages.
*p Value <0.05. (B) Plasma IgM and IgG concentrations were quantiﬁed
before infection (Ctl, diamonds) and 7, 14, 21, and 28 dpi (ﬁlled circles).
Horizontal bars indicate the median concentrations. Statistically signiﬁcant
differences are indicated (*p<0.05; **p<0.01; ***p<0.001). (C) IgG,
IgM, and IgA SIV-speciﬁc Ab concentrations in the plasma of SIV-infected
macaques 14, 21, and 28 dpi. Horizontal bars indicate the median OD
values. *p Value <0.05.
www.frontiersin.org December 2011 | Volume 2 | Article 63 | 7
Zouali and Richard Marginal zone B-cells
Indeed, we observed an increased density of IgG plasma cells in
the MZ and the red pulp, and augmented plasma IgG and IgM
levels before 14 dpi. In contrast, new IgG and IgM plasma cells
in GCs and plasma SIV-speciﬁc Ab were only detectable after
21 dpi. It is possible that SIV-induced soluble FasL and TRAIL,
or a direct interaction between gp120 and VH3-expressing BCRs
contributed to this MZ B-cell apoptosis (Berberian et al., 1993;
Karray and Zouali, 1997; Samuelsson et al., 1997; Herbeuval et al.,
2006). Since gp120-induced production of BAFF by monocytes
can enhance polyclonal IgG production by a subset of MZ B-
cells (He et al., 2006), the Ig production we saw would rather be
promoted by increased cytokine production, including BAFF and
APRIL (Ettinger et al., 2007). Consistently, we observed a tran-
sient increase in plasma BAFF levels with a peak on 11–12 dpi.
During the acute phase of infection, increased plasma levels corre-
lated with plasma viral load,CD4 T-cell depletion and plasma IgG.
In these SIV-infected macaques, no change in plasma APRIL was
observed (YolandeRichard,unpublisheddata).As previous studies
in the mouse suggest (Lesley et al., 2004; Thien et al., 2004), BAFF
overexpression may also contribute to the preferential production
of polyclonal or autoreactive Ab at the expense of SIV-speciﬁc Ab.
As MZ and switched memory B-cells home together in the
spleen MZ, their concomitant depletion during the acute phase of
infection is intriguing, and may suggest the existence of a com-
mon mechanism. In viremic HIV-infected patients, a sustained
BAFF overexpression was postulated to impair the trafﬁcking
of B-cells between the MZ and B-cell follicles (Fontaine et al.,
2011). In support to this conclusion, we had previously shown
that in vitro short-term exposure of human B-cells to BAFF pref-
erentially increased the chemotactic response of CD27+ B-cells
to CXCL13 (Badr et al., 2008). It is possible that type I IFN and
BAFF, produced early during the acute phase of infection, may
increase the retention of MZ B-cells into B-cell follicles, decrease
the import of virus particles, and delay the onset of virus-speciﬁc
TD responses. This hypothesis is consistent with SIV-speciﬁc Ab
being detectable in the serumonly after the decrease of plasma type
I IFN and BAFF (e.g., after 16 dpi). A better understanding of the
mechanisms and consequences of this death on the Ab response
will be essential for vaccine development.
CONCLUSIONS
As discussed above, MZ B-cells are a ﬁrst-line of defense against
blood-borne pathogens entering the spleen freely through the
blood or transported by circulatingAPCs. They represent themain
B-cell population involved in the generation of rapid TI responses
to blood-borne bacteria. They play an important role in the pro-
duction of earlyAb responses against infectious bacterial and virus
particles. Splenectomized mice or mice lacking functional MZ B-
cells produce delayedAb responses to infectious agents that require
T-cell collaboration. The easy accessibility of MZ B-cells to blood-
borne Ags, their lower threshold of activation, and the enrichment
in clones speciﬁc for TI antigens account for the critical role that
this B-cell subset plays in the induction of rapid TI Ab responses.
Taking into account that infectious agents are complex and
composed of both TD and TI epitopes, MZ B-cells are likely to
be heterogeneous, multireactive, and react with a wide variety of
pathogen-associated Ags. Yet, the observations summarized above
and obtained in a model of mice expressing human Igs (Viau et al.,
2004a,b, 2005, 2007; Viau and Zouali, 2005) and in a non-human
primate (Peruchon et al., 2009) revealed that viruses and bacteria
have developed strategies to deplete MZ B-cells during the acute
phase of infection. Unraveling the intimate mechanisms responsi-
ble for targeting MZ B-cells in humans and non-human primates
will be important for understanding disease pathogenesis and for
designing novel vaccine formulations.
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